NEW HAVEN, CT – Lisa Delfini, the Chief Financial Officer of Trevi Therapeutics, Inc. (NASDAQ:TRVI), a pharmaceutical company specializing in therapeutic preparations, has conducted transactions in the company's stock, as reported in a recent SEC filing. On May 22, 2024, Delfini sold 4,350 shares of common stock at weighted average prices ranging from $2.64 to $2.65, totaling approximately $11,484.
The transactions occurred on the same day that Delfini exercised options to acquire 16,043 shares of common stock at a price of $0.511 per share, totaling $8,197. These shares were acquired through a stock option right to buy, which was granted on February 11, 2022, with a portion of the shares vesting on February 11, 2023, and the remainder to vest in equal monthly installments through February 11, 2026.
Following these transactions, Delfini's ownership in Trevi Therapeutics' common stock adjusted to 53,279 shares, which includes 5,685 shares purchased through the company's employee stock purchase plan. The sale of shares by Delfini was partly to meet tax withholding obligations arising from the exercise of the stock options.
These financial moves by a top executive at Trevi Therapeutics provide insights into the trading activities of the company's insiders. The details, including the number of shares sold at each price within the reported range, are available upon request from the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission.
Investors and followers of Trevi Therapeutics will be keeping a close watch on the company's stock performance and any further transactions by its executives.
InvestingPro Insights
As investors digest the recent stock transactions by Lisa Delfini, CFO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), it's important to consider the company's financial health and market performance. According to InvestingPro data, Trevi Therapeutics has a market capitalization of $176.09 million and is facing significant challenges, as evidenced by its negative P/E ratio of -7.44, which further adjusted to -5.25 in the last twelve months as of Q1 2024. This suggests that investors are wary about the company's profitability in the near term.
An InvestingPro Tip highlights that Trevi Therapeutics holds more cash than debt on its balance sheet, which is a positive sign of liquidity. However, another tip points out that the company is quickly burning through cash, which could raise concerns about its long-term financial stability. With analysts revising their earnings downwards for the upcoming period, and an expectation of net income dropping this year, these insights could be crucial for investors considering the company's prospects.
Despite a large price uptick over the last six months, with a 120.87% return, the stock has taken a significant hit over the last week, experiencing an 8.3% price total return decrease. This volatility underscores the importance of staying informed through real-time data and expert analysis. For those looking for more in-depth analysis, InvestingPro offers additional tips on Trevi Therapeutics, which can be accessed at https://www.investing.com/pro/TRVI. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover the 10 additional tips listed on InvestingPro that can help you make more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.